Bio-Rad Laboratories, Inc. (NYSE:BIO) Stock Position Lifted by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. grew its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 9.2% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 109,051 shares of the medical research company’s stock after buying an additional 9,185 shares during the period. Envestnet Asset Management Inc. owned about 0.38% of Bio-Rad Laboratories worth $29,783,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in BIO. Capital Advisors Ltd. LLC lifted its holdings in shares of Bio-Rad Laboratories by 193.8% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock worth $26,000 after purchasing an additional 62 shares during the last quarter. Sound Income Strategies LLC bought a new stake in Bio-Rad Laboratories during the 1st quarter valued at $38,000. Principal Securities Inc. bought a new stake in Bio-Rad Laboratories during the 4th quarter valued at $41,000. EntryPoint Capital LLC bought a new stake in Bio-Rad Laboratories during the 1st quarter valued at $51,000. Finally, Headlands Technologies LLC bought a new stake in Bio-Rad Laboratories during the 2nd quarter valued at $51,000. Institutional investors own 65.24% of the company’s stock.

Insider Buying and Selling

In related news, COO Andrew J. Last sold 3,000 shares of Bio-Rad Laboratories stock in a transaction on Friday, September 6th. The stock was sold at an average price of $329.94, for a total value of $989,820.00. Following the transaction, the chief operating officer now directly owns 7,559 shares in the company, valued at approximately $2,494,016.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, COO Andrew J. Last sold 3,000 shares of Bio-Rad Laboratories stock in a transaction on Friday, September 6th. The stock was sold at an average price of $329.94, for a total transaction of $989,820.00. Following the transaction, the chief operating officer now owns 7,559 shares in the company, valued at $2,494,016.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total value of $205,895.27. Following the transaction, the executive vice president now owns 147 shares in the company, valued at approximately $48,582.03. The disclosure for this sale can be found here. Insiders own 17.06% of the company’s stock.

Bio-Rad Laboratories Stock Down 4.2 %

Shares of BIO stock opened at $330.01 on Friday. Bio-Rad Laboratories, Inc. has a 1 year low of $261.59 and a 1 year high of $366.30. The stock has a market cap of $9.41 billion, a PE ratio of -31.85 and a beta of 0.95. The business’s fifty day moving average is $323.76 and its 200-day moving average is $307.68. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 6.28.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, August 1st. The medical research company reported $3.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.12 by $0.99. The business had revenue of $638.50 million for the quarter, compared to analysts’ expectations of $645.79 million. Bio-Rad Laboratories had a positive return on equity of 3.77% and a negative net margin of 51.73%. The company’s quarterly revenue was down 6.3% on a year-over-year basis. During the same period in the previous year, the firm posted $3.00 EPS. Equities analysts expect that Bio-Rad Laboratories, Inc. will post 10.31 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have weighed in on BIO. Citigroup lifted their target price on Bio-Rad Laboratories from $300.00 to $350.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. Wells Fargo & Company began coverage on Bio-Rad Laboratories in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 target price on the stock. StockNews.com downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Royal Bank of Canada reiterated an “outperform” rating and set a $401.00 price target on shares of Bio-Rad Laboratories in a research report on Friday, August 16th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $315.00 price target (down from $440.00) on shares of Bio-Rad Laboratories in a research report on Monday, June 3rd. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $358.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.